Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 437-446

  Vijayvergia, Namrata ^a   Mehra, Ranee ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ALK inhibitors; Anaplastic lymphoma kinase; Diagnostics; Non small cell lung cancer; Resistance

Indexed keywords

(2,4 DIHYDROXY 5 ISOPROPYLPHENYL)[5 [(4 METHYL 1 PIPERAZINYL)METHYL] 2 ISOINDOLINYL]METHANONE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANTINEOPLASTIC AGENT; AP 26113; ASP 3026; ASPARTATE AMINOTRANSFERASE; AT 13387; AZD 3463; BILIRUBIN; CEP 28122; CERITINIB; CRIZOTINIB; GANETESPIB; LUMINESPIB; PEMETREXED; RETASPIMYCIN; RO 5424802; TRS 011; TSR 011; UNCLASSIFIED DRUG; X 396; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ADVANCED CANCER; ALK GENE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER RESISTANCE; CANCER SCREENING; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG ACTIVITY; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; DYSGEUSIA; EDEMA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE; GENE REARRANGEMENT; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; NAUSEA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84907598750     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2517-6     Document Type: Review

References (83)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9-29
2. NCI Surveillance Epidemiology and End Results. From http://seer.cancer. gov/statfacts/html/lungb.html#survival. Accessed March 2014
3. Li Y, Ye X, Liu J, Zha J, Pei L (2011) Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors. Neoplasia 13:1-11
4. Sharma SV, Fischbach MA, Haber DA, Settleman J (2006) "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12:4392s-4395s (Pubitemid 44197187)
5. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284 (Pubitemid 24107549)
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566 (Pubitemid 47206930)
7. Mano H (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99:2349-2355
8. Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K (2012) Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol 23:2931-2936
9. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14:6618-6624
10. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703
11. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283
12. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8:11-23
13. Shaw AT, Solomon B (2011) Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 17:2081-2086
14. Mosse YP, Balis FM, Lim MS, Laliberte J, Voss SD, Fox E, Bagatell R, Weigel B, Adamson PC, Ingle AM, Ahem CH, Blaney S (2012) Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J Clin Oncol 30(suppl):[abstract 9500]
15. Solomon B, Varella-Garcia M, Camidge DR (2009) ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 4:1450-1454
16. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971-4976
17. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y, Mano H (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143-3149
18. Weickhardt AJ, Camidge DR (2011) The therapeutic potential of eneplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Investig 1:1119-1126
19. Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, University of Hong Kong Lung Cancer Study Group (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723-1733
20. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S, Choe JY, Chung JH (2012) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76:403-409
21. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M (2010) Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 16:5581-5590
22. Varella-Garcia M, Cho Y, Lu X, Baron AE, Terracciano L, Camidge DR, Bunn PA, Jr., Franklin WA, Cappuzzo F, Doebele RC (2010) ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). J Clin Oncol 28(15 s):[abstract 10533]
23. Kris MG, Johnson BE, Kwatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, Garon EB, Pao W, Schiller JH, Haura EB, Shirai K, Giaccone G, Berry LD, Kugler K, Minna JD, Bunn PA (2011) Identification of driver mutations in tumor specimens from 1,000 patients with adenocarcinoma: the NCI's cancer mutation consortium (LCMC). J Clin Oncol 29(suppl):[abstract CRA7506]
24. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT (2013) ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with non-small cell lung cancer. Clin Cancer Res 19:4273-4281
25. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R, Okubo K, Manabe T, Date H (2010) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17:889-897
26. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K, Soda M, Choi YL, Mano H, Ishikawa Y (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22:508-515
27. Koh Y, Kim DW, Kim TM, Lee SH, Jeon YK, Chung DH, Kim YW, Heo DS, Kim WH, Bang YJ (2011) Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 6:905-912
28. Shaw AT, Yeap B, Costa DB, Solomon BJ, Kwak EL, Nguyen AT, Bergethon K, Engelman JA, Iafrate AJ (2010) Prognostic versus predictive value of EML4-ALK translocation in metastatic nonsmall cell lung cancer. J Clin Oncol 28(15 s):[abstract 7606]
29. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253
30. Atherly AJ, Camidge DR (2012) The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer 106:1100-1106
31. NCCN Guidelines: NSCLC. 2014:v3
32. Kim D, Ahn M, Shi Y, Yang P, Liu X, De Pas TM, Crino L, Lanzalone S, Polli A, Shaw AT (2012) Updated results of a global phase II study with crizotinib in advanced ALK-positive nonsmall cell lung cancer. European Society for Medical Oncology Congress:[abstract 1230PD]
33. Shaw AT, Solomon B, Kenudson MM (2011) Crizotinib and testing for ALK. J Natl Compr Canc Netw 9:1335-1341
34. Sanders HR, Li HR, Bruey JM, Scheerle JA, Meloni-Ehrig AM, Kelly JC, Novick C, Albitar M (2011) Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 204:45-52
35. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, Erickson-Johnson MR, Caron BL, Li Y, Tang H, Stoddard S, Wampfler J, Kulig K, Yang P (2011) Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6:459-465
36. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Janne PA, Iafrate AJ, Rodig SJ (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571
37. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6:466-472
38. McLeer-Florin A, Moro-Sibilot D, Melis A, Salameire D, Lefebvre C, Ceccaldi F, de Fraipont F, Brambilla E, Lantuejoul S (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7:348-354
39. Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77:288-292
40. Ventana Medical Systems, Inc. From http://www.ventana.com/site/page?view= press-release-oct25-2012. Accessed March 2014
41. Lee JK, Park HS, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH, Heo DS, Kim WH, Bang YJ (2012) Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 118:3579-3586
42. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC (2012) Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118:729-739
43. Gandara DR, Huang E, Desai S, Mack PC, Beckett L, Stephens C, Zeger G, Denenberg KD, Maus MKH, Li T (2012) Thymidylate synthase (TS) gene expression in patients with ALK positive (ALK+) non-small cell lung cancer (NSCLC): Implications for therapy. J Clin Oncol 30(suppl):[abstract 7582]
44. Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ (2013) Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer 79:40-45
45. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC (2011) Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 6:774-780
46. Shaw AT, Varghese AM, Solomon BJ, Costa DB, Novello S, Mino-Kenudson M, Awad MM, Engelman JA, Riely GJ, Monica V, Yeap BY, Scagliotti GV (2013) Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Ann Oncol 24:59-66
47. Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK (2006) Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428-2436 (Pubitemid 43787667)
48. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011-1019
49. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394
50. Berge EM, Lu X, Maxson D, Baron AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M, Camidge DR (2013) Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer 14:636-643
51. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA (2012) Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4:120ra17
52. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18:1472-1482
53. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H, Ishikawa Y, Kimura H, Mitsudomi T, Tanio Y, Mano H, ALK Lung Cancer Study Group (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739
54. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4 - ALK. Proc Natl Acad Sci USA 108:7535-7540
55. Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K (2012) Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 18:6219-6226
56. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY (2013) Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- (isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 56:5675-5690
57. Li N, Michellys P, Kim S, Culazzo Pferdekamper A, Li J, Kasibhatla S, Tompkins CS, Steffy A, Li A, Sun F, Sun X, Hua S, Tiedt R, Sarkisova Y, Marsilje TH, McNamara P, Harris J (2011) Activity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor models. Mol Cancer Ther 10:[abstract B232]
58. Shaw AT, Kim D, Mehra R, Tan DS, Felip E, Chow LQM, Camidge DR, Vansteenkiste JF, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau Y, Goldwasser M, Boral AL, Engelman JA (2014) LDK378 in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. N Engl J Med 370:1189-1197
59. LDK378 Breakthrough Therapy designation. From www.novartis.com/newsroom/ media-releases/en/2013/1685517.shtml. Accessed March 2014
60. Shaw AT, Camidge DR, Felip E, Sharma S, Tan SW, Kim D, De Pas T, Vansteenkiste JF, Santoro A, Liu G, Chow LQM, Goldwasser M, Lau Y, Boral AL, Mehra R (2012) Results of the first-in-human phase I study of the ALK inhibitor LDK378 in advanced malignancies. European Society for Medical Oncology Congress:[abstract 440O]
61. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679-690
62. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, openlabel, phase 1-2 study. Lancet Oncol 14:590-598
63. Ou S, Gadgeel SM, Chiappori A, Riely G, Lee R, Garcia L, Kikuchi H, Tatsuno M, Tanaka T, Gandhi L (2013) Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028). European Society for Medical Oncology Congress:[abstract LAB44]
64. Zhang S, Wang F, Keats.J., Ning Y, Wardwell SD, Moran L, Mohemmad QK, Ye E, Anjum R, Wang Y, Zhu X, Miret JJ, Delgarno D, Narasimhan NI, Clackson T, Shakespeare WC, Rivera VM (2010) AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066. Cancer Res 70(suppl):[abstract LB-298]
65. Camidge DR, Bazhenova L, Salgia R, Weiss GJ, Langer CJ, Shaw AT, Narasimhan NI, Dorer DJ, Rivera VM, Zhang J, Clackson T, Haluska FG, Gettinger SN (2013) First-in-human dosefinding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. J Clin Oncol 31(suppl):[abstract 8031]
66. Camidge DR, Bazhenova L, Salgia R, Weiss GJ, Langer CJ, Shaw AT, Narasimhan NI, Dorer DJ, Zhang J, Gettinger SN (2013) Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. European Society for Medical Oncology Congress:[abstract 3401]
67. Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C (2013) Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res 11:122-132
68. Bonvini P, Gastaldi T, Falini B, Rosolen A (2002) Nucleophosmin- anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin. Cancer Res 62:1559-1566 (Pubitemid 34407823)
69. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068-3077
70. Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28:4953-4960
71. Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, Kuppers R, Thomas RK (2012) Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 18:4682-4690
72. Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Baron AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR (2012) Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 118:4502-4511
73. Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD (2012) Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 13:1376-1383
74. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, Wilner KD (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443-e445
75. Weickhardt AJ, Scheler B, Burke JM, Gan G, Doebele RC, Bunn PA, Gaspar LE, Kavanagh BD, Camidge DR (2012) Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol 30(suppl):[abstract 7526]
76. Otterson GA, Riely GJ, Shaw AT, Crino L, Kim D, Martins R, Salgia R, Zhou C, Solomon BJ, Wilner KD, Poli A, Tang Y, Bartlett CH, Ou SI (2012) Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management. J Clin Oncol 30(suppl):[abstract 7600]
77. Takeda M, Okamoto I, Nakagawa K (2013) Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 8:654-657
78. Gandhi L, Drappatz J, Ramaiya NH, Otterson GA (2013) Highdose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer. J Thorac Oncol 8:e3-e5
79. Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixido J, Costa C, Borrell JL (2013) ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer 2:72-86
80. Wilcoxen KM, Brake RL, Saffran D, Taffera Y, Choquette D, Whittington D, Yu V, Romero K, Bode C, Stellwagen J, Potashman M, Emkey R, Andrews P, Drew AE, Xu M, Szilvassy S, Al-Assad S, Lewis RT (2012) Characterization of a novel series of potent, selective inhibitors of wild-type and mutant/fusion anaplastic lymphoma kinase. Cancer Res 72(suppl):[abstract 1795]
81. + NSCLC. E European Society for Medical Oncology Congress:[abstract P417]
82. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 71:4920-4931
83. Drew L, Cheng J, Engelman J, Ferguson D, Katayama R, McDermott B, Saeh J, Shaw A, Shen M, Widzowski D, Wu A, Smith G (2013) AZD3463, a novel ALK/IGF1R inhibitor, overcomes multiple mechanisms of acquired resistance to crizotinib. Cancer Res 73(suppl):[abstract 919]